Learn more about the benefits of registering on the new BJS website

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. BJS 2006; 93: 1270-1276.

Published: 13th July 2006

Authors: T. D. Yan, M. Links, Z. Y. Xu, P. C. Kam, D. Glenn, D. L. Morris et al.


Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been used to treat pseudomyxoma peritonei. The aim of this prospective study was to evaluate survival outcome and treatment‐related prognostic markers in patients who underwent CRS and PIC for pseudomyxoma peritonei from appendiceal mucinous neoplasms.


Survival data and 12 clinicopathological and treatment‐related prognostic variables for survival were obtained prospectively in 50 consecutive patients (23 men). Univariate analysis was used to determine their prognostic significance for overall survival, determined from the time of CRS.


The mean(s.d.) age was 52(12) years. Eighteen patients had moderate complications, and six patients had severe complications that required operation or intensive care support. Two patients died after surgery. The actuarial 5‐year survival rate was 69 per cent. Univariate analysis demonstrated that the extent of previous surgery (P = 0·045) and Ronnett's histopathological classification (P < 0·001) were significantly related to overall survival.


CRS combined with PIC was associated with improved survival in patients with less extensive previous surgery and diffuse peritoneal adenomucinosis histopathological type. Copyright © 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Full text

Your comments